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ABSTRACT
Background: Although HIV-1 infection   predisposes an 
individual to well defined neoplasia, neurofibromas have 
not been reported as some of  the typical ones. The 
a s s o c i a t i o n  b e t w e e n  H I V- 1  i n f e c t i o n  a n d  
neurofibromatosis type 1, a genetic disorder, should be of  
interest because HIV infection could alter the natural 
biology of  its cutaneous manifestations. However, reports 
on simultaneous occurrence of  these conditions in an 
individual are rare. 
Method: The case records of  a 30 year old HIV 1 positive 
female receiving care at the Jos University teaching 
hospital centre and a review of  the relevant literature was 
utilised.
Result: We present a 30 year old HIV positive woman with 
florid cutaneous lesions of  familial neurofibromatosis type 
1 who had adequate response to antiretroviral therapy
Conclusion: HIV infection and treatment did not seem to 
affect the clinico- pathological features of  the 
neurofibromatosis lesions.
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condition but can be complicated by plexiform 
nuerofibroma, pseudoarthosis, epilepsy, spinal 
neuro?bromas,  aqueducta l  s tenos is,  v i scera l  
5neuro?bromas and haematological malignancies.
Many HIV-associated tumours affect sites that are in 
contact with the outside environment, including the skin. 
The increased density of  immune cells and coincident 
elevated concentration of  HIV-1 at these sites could lead to 
local compromised immune defences and the subsequent 
6,7development of  neoplasms.  Although it is unclear if  HIV-
1 acts directly as an oncogenic agent, it may contribute to 
the development of  neoplasms through several 
mechanisms. Predisposition to infection by oncogenic 
viruses, impaired immune surveillance, dysregulation of  
cytokine pathways and growth factor production, chronic 
B cell stimulation, and imbalance between cellular 
proliferation and differentiation may all contribute to the 
6,8,9development of  HIV/AIDS-associated neoplasia.  
Hence, it is plausible that increased risk for neoplasia, 
altered appearance of  lesions and natural course of  
diseases can be more profound in individuals with 
concurrent HIV-1 infection and NF 1.  We report this case 
to draw attention to rarely reported occurrence of  HIV 
infection in a patient with NF 1, and whether HIV-1 
infection can influence the course of  NF 1 lesions.
CASE REPORT
Our patient is a 30-year old female trader who was first seen 
in the HIV outpatient clinic of  the Jos University Teaching 
Hospital (JUTH), Jos, Nigeria about a year ago and was 
diagnosed as having WHO stage 1 HIV-1 disease. She also 
presented with a history of  multiple skin growths all over 
the body since childhood. The growths had increased in 
size and number but have remained virtually the same in 
the last couple of  years. There were no associated 
symptoms in all the other body systems. She is the fifth of  
seven siblings. Her mother, who died of  obstetric 
complications, her younger sister and her 13 year old child, 
had similar skin lesions. She is a single mother who does 
not smoke cigarettes or drink alcohol.
Physical examination revealed a young woman with 
extensive soft sessile and pedunculated nodules mostly on 
the trunk, numerous cafe-au-lait spots and axillary 
freckling (Figure 1). The largest nodule measured 8cm by 
4cm while over 10 cafe-au-lait spots were more than 1.5cm 
in diameter each. The rest of  the examination was 
unremarkable.  Her baseline CD4+ cell count and HIV-1 
viral load were 126 cells/µl and 12,494 copies/ml 
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INTRODUCTION
Neurofibromatosis type 1 (NF 1) or Von Recklinghausen's 
disease is a neurocutaneous disorder that mainly affects the 
skin and peripheral nervous system and causes 
characteristic bony dysplasia. It has a birth incidence of  
one in 2500 to  3000 and a prevalence of  one in 4000 to 
 15000 in the UK.  Although NF 1 is not uncommon in sub-
2,3saharan Africa,  literature on NF 1 co-existing with  HIV 
infection are  rare.  
The gene for NF1 is cloned on chromosome 17q11.2 and 
encodes a protein called neurofibromin which has a role in 
tumour suppression. Neuro?bromin reduces cell 
proliferation by accelerating the inactivation of  a cellular 
proto-oncogene, p21 ras, which is important in promoting 
4tumour formation.  Inactivation of  the gene through 
mutation or allelic loss leads to loss of  function and 
subsequent development of  many different types of  
tumours seen in the disease. NF 1 is largely a benign 
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respectively. Histopathological section of  one nodule showed 
bundle of  masses with spindle-shaped cells and waxy 
cytoplasm revealing a cellular and loose area consistent with 
a neurofibroma (Figure 2). A diagnosis of  NF 1 based on the 
National Institute of  Health Consensus Development 
10Conference (NIHCDC) criteria  with AIDS was made and 
she commenced Nevirapine based Highly Active 
Antiretroviral Therapy (HAART). She ?was? offered? 
genetic ?counselling, scheduled? for? regular clinical? 
review? ?for her HIV disease and ?surveillance  ?of  ?the 
?nodules,? and? any? conditions ?that ?may? be? 
associated ?with ?neurofibromatosis. She became 
virologically suppressed at 12 weeks of  HAART while her 
CD4+ cell count rose to  291 cells/ µl at one year of  HAART. 
She did not develop any opportunistic disease and there has 
not been any appreciable change in the neurocutaneous 
features or development of  any condition related to NF 1 
within the one year follow-up period.
in 16 (34%) of  patients who presented at the surgery 
department. However, contrasting our findings, Odebode et 
11al  in a study of  98 patients reported the lower limbs as the 
most frequently affected site and none of  the patients had skin 
freckling. Due to high awareness and prevalence of  florid skin 
12diseases in HIV infection,  the HIV clinician can expect to be 
consulted for diseases referable to other specialties. 
Although the diagnosis of  NF 1 was easy in our patient, skin 
lesions in AIDS tend to display unusual clinical and biologic 
behaviour. Furthermore, among other lesions, Kaposi's 
sarcoma, the commonest cutaneous tumour in HIV/AIDS 
may resemble plexiform or small sparsely distributed 
13,14neurofibromas.  Therefore, diagnostic challenge may arise 
with possible grave consequence if  missed.  
While the natural course of  NF 1 over time is poorly 
understood, neurofibromas and cafe-au-lait spots generally 
increase in size and numbers from childhood through 
15adolescence levelling off  in adulthood.  That our patient 
presented in adulthood when the cutaneous manifestations 
 of  NF 1 reportedly level off  may explain the apparent lack of  
change in the lesions despite her HIV induced immune 
suppression. In addition, we are unable to say for how long 
our patient has had immunological AIDS; whether immune 
reconstitution due to HAART staved off  any possible change 
in the lesions; whether the one year period under review is too 
short for any noticeable change to occur or that indeed, her 
HIV infection did not influence the natural course of  the NF 1 
lesions.
CONCLUSION
The profound HIV induced immune suppression did not 
seem to impact NF 1 in our patient. However, large studies in 
which patients are followed over an extended period of  time 
are needed to better explore possible interactions between 
HIV infection and NF 1. 
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(Figure 1). Clinical Picture of  Neurofibromatosis type 1: A
Figure 2: Histology Section of Neurofibromatosis type 1: A
DISCUSSION
We report the case of  a 30 year old woman with NF 1 and 
immunological AIDS who presented to our HIV clinic with 
florid neurofibromas mostly on the trunk, cafe-au-lait spots 
and axillary freckling. Her NF 1 disease remained stable and 
she had adequate response to HAART for the HIV disease.
3Similar to our findings, Nyandaiti et al  reported a mean age 
of  28 years and the trunk as the commonest neurofibroma site 
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